Given the convenience and cost-savings of shopping at the local store for GI antidotes, consumers are increasingly more willing to self-medicate. However, private-label brands have successfully muscled in on this growth in demand. To wit: sales for Prilosec OTC peaked at about $387 million back in 2006. Additionally, Prilosec has now lost market exclusivity (held since 2003) — the FDA has approved for OTC purchase two other branded PPIs. Read More….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.